Organization
Pfizer Inc, Montreal, QC, Canada
2 abstracts
Abstract
AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIESOrg: Pfizer Inc, Montreal, QC, Canada, Pfizer Inc, Sollentuna, Sweden, Pfizer Inc, Groton, CT, United States of America, Pfizer Inc, Peapack, NJ, United States of America, Pfizer Inc, Collegeville, PA, United States of America,
Abstract
BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITISOrg: Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of america, UZ Leuven, Leuven, Belgium, Pfizer Inc, Groton, CT, United States of America, Swedish Medical Center and University of Washington, Seattle, WA, United States of america, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, United States of america,